Article

Predictors of physical aggression in children with attention-deficit/hyperactivity disorder

Neuropsychology Doctoral Subprogram in Psychology, The Graduate Center, City University of New York, New York, NY, USA.
CNS spectrums (Impact Factor: 1.3). 07/2000; 5(6):52-7.
Source: PubMed

ABSTRACT The present investigation examined factors that predict physical aggression in children with attention-deficit/hyperactivity disorder (ADHD). Stepwise, multiple regression-analyses were used to examine predictors of children's physical aggression as rated by parents at a 1-year follow-up point and by teachers at both 1- and 2-year follow-up points. Early parent and teacher ratings of verbal aggression (ie, cursing, teasing, and threatening) accounted for the greatest proportion of the variance in physical aggression ratings obtained at follow-up. None of the other predictor variables, including early ratings of physical aggression and ADHD behaviors, contributed significant additional variance beyond that accounted for by early verbal aggression ratings. Temporal and cross-informant analyses revealed that the relationship between verbal aggression and later physical aggression was situation-specific for teacher ratings but not parent ratings. Although physical aggression may emerge early in development, these data suggest that verbal aggression represents a stable, temperamental characteristic that may be of greater value than early physical aggression for predicting later physically aggressive acts.

0 Followers
 · 
57 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article will present a group play therapy model designed for youth that present with Attention Deficit Disorder/Attention-Deficit/Hyperactivity Disorder (ADD/ADHD) symptomalogy. These symptoms include, but are not limited to impulsivity, disruptive behaviors, social skill deficits as well as ineffective communication skills. This model, unlike current deficit, psychoeducational models, is based in a play therapy, process-oriented framework. The model utilizes concepts from attribution theory as well as social learning theory to assist in skill enhancement and practical social experience. The research on this program will demonstrate a positive impact showing a significant increase in self-esteem, which ultimately allows for a heightened level of functioning and overall increased ability to engage in socially acceptable behavior.
    Journal of Child and Adolescent Group Therapy 11/2000; 10(4):191-211. DOI:10.1023/A:1016631228545
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuroprotective treatments are therapies designed to interrupt the cellular, biochemical, and metabolic elaboration of injury during or following exposure to ischemia; they encompass a rapidly expanding array of pharmacologic interventions. Various classes of neuroprotective agents have reached phase III efficacy trials in focal ischemic stroke, but none has proven effective, despite successful preceding animal studies. This notwithstanding, recent favorable results of hypothermia in human cardiac arrest trials have validated the general concept of neuroprotection. In addition, the promise of neuroprotective therapy for focal acute ischemic stroke has been renewed by innovations in strategies of preclinical drug development and clinical trial design that rectify past defects, including trial testing of combination therapies rather than single agents and novel approaches to accelerating time to initiation of experimental treatment.
    Current Neurology and Neuroscience Reports 02/2003; 3(1):9-20. DOI:10.1007/s11910-003-0031-z · 3.67 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently, intravenous recombinant tissue plasminogen activator is the only US Food and Drug Administration-approved therapy for acute ischemic stroke. Although efficacious, its usefulness is limited, mainly because of the very limited time window for its administration. Neuroprotective treatments are therapies that block the cellular, biochemical, and metabolic elaboration of injury during or after exposure to ischemia, and have a potential role in ameliorating brain injury in patients with acute ischemic stroke. More than 50 neuroprotective agents have reached randomized human clinical trials in focal ischemic stroke, but none has been unequivocally proven efficacious, despite successful preceding animal studies. The failed neuroprotective trials of the past have greatly increased understanding of the fundamental biology of ischemic brain injury and have laid a strong foundation for future advance. Moreover, the recent favorable results of human clinical trials of hypothermia in human cardiac arrest and global brain ischemia have validated the general concept of neuroprotection for ischemic brain injury. Recent innovations in strategies of preclinical drug development and clinical trial design that rectify past defects hold great promise for neuroprotective investigation, including novel approaches to accelerating time to initiation of experimental treatment, use of outcome measures sensitive to treatment effects, and trial testing of combination therapies rather than single agents alone. Although no neuroprotective agent is of proven benefit for focal ischemic stroke, several currently available interventions have shown promising results in preliminary trials and may be considered for cautious, off-label use in acute stroke, including hypothermia, magnesium sulfate, citicoline, albumin, and erythropoietin. Overall, the prospects for safe and effective neuroprotective therapies to improve stroke outcome remain promising.
    Current Treatment Options in Neurology 10/2003; 5(5):367-375. DOI:10.1007/s11936-003-0033-9 · 2.18 Impact Factor
Show more